Thanks to this 100% online Master's Degree, you will master the most innovative microbiological diagnostic techniques and design highly personalized therapeutic interventions” 

The management of Infectious Diseases is a constant challenge for medical professionals.  The increasing resistance to antibiotics, along with the persistence of conditions such as Dengue, Typhoid Fever, and Leptospirosis, makes continuous updating in this field essential.  Additionally, the emergence of new viral strains with greater transmission capacity demands advanced strategies for diagnosis, treatment, and prevention. 

In response to this reality, TECH’s Master's Degree in Clinical Infectious Diseases and Advanced Antibiotic Therapeutics provides comprehensive and up-to-date training. The educational materials will cover the latest advances in epidemiology, severe respiratory infections, bacterial resistance, and vaccine development. The impact of the pharmaceutical and biotechnology industries in the fight against these diseases will also be explored. 

This program not only expands specialized knowledge but also opens new career opportunities.  Graduates will be able to work in leading hospitals, research centers, public health organizations, the pharmaceutical industry, and institutions dedicated to the prevention and treatment of Infectious Diseases. 
One of the major benefits of this program is its 100% online format, with no in-person classes or fixed schedules.  Additionally, the content is available from day one, allowing students to organize their study time according to their availability. Accessible from any device with an internet connection, it offers total flexibility and compatibility with professional life. 

With this qualification, physicians will acquire key tools to tackle current and future challenges in the field of infectious diseases, positioning themselves as specialists in a critical area for global public health.  
Furthermore, a prestigious International Guest Director will deliver 10 exclusive Masterclasses. 

A renowned International Guest Director will deliver 10 intensive Masterclasses on the latest advancements in Clinical Infectious Diseases and Advanced Antibiotic Therapeutics” 

This Master's Degree in Clinical Infectious Diseases and Advanced Antibiotic Therapeutics contains the most complete and up-to-date university program on the market" Its most notable features are:

• The development of practical case studies presented by experts in Medicine 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice 
• Practical exercises where the self-assessment process can be carried out to improve learning 
• Its special emphasis on innovative methodologies in the management of the audiovisual industry 
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 

You will master advanced microbiological diagnostics, including molecular biology techniques, genomic sequencing, and antimicrobial susceptibility testing” 

The teaching staff includes professionals belonging to the field of medicine, who contribute their work experience to this program, as well as renowned specialists from reference societies and prestigious universities. 

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive learning experience designed to prepare for real-life situations. 

This program is designed around Problem-Based Learning, whereby the student must try to solve the different professional practice situations that arise throughout the program. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts. 

You will delve into the pathophysiology of Infectious Diseases, analyzing their epidemiology, transmission, and clinical progression"

Thanks to TECH Relearning you will be able to assimilate the essential concepts in a fast, natural and accurate way"

This Master's Degree in Clinical Infectious Diseases and Advanced Antibiotic Therapeutics offers in-depth and up-to-date specialization in the diagnosis, treatment, and control of complex infections. Through a practical and innovative approach, the program explores everything from the most advanced antimicrobial therapies to the latest trends in biotechnology applied to healthcare. With a syllabus designed for flexibility and autonomous learning, this Master's Degree will enable you to make a difference in a critical area of Medicine. 

You will optimize antibiotic prescription by applying principles of pharmacokinetics and pharmacodynamics to enhance the effectiveness of therapies” 

Module 1. Epidemiology and Microbiology of Infectious Diseases 

1.1. Epidemiological, Economic, and Social Conditions by Continent that Favor the Development of Infectious Diseases 

1.1.1. Africa 
1.1.2. America 
1.1.3. Europe and Asia 

1.2. New and Emerging Diseases By Continent 

1.2.1. Morbidity and Mortality from Infectious Diseases in Africa 
1.2.2. Morbidity and Mortality from Infectious Diseases in America 
1.2.3. Morbidity and Mortality from Infectious Diseases in Asia 
1.2.4. Morbidity and Mortality from Infectious Diseases in Europe 

1.3. Taxonomy of Infectious Agents 

1.3.1. Viruses 
1.3.2. Bacteria 
1.3.3. Fungi 
1.3.4. Parasites 

1.4. Properties of Microorganisms to Cause Disease 

1.4.1. Pathogenicity Mechanisms 
1.4.2. Adhesion and Multiplication Mechanisms 
1.4.3. Mechanisms that Allow Nutrient Acquisition from the Host 
1.4.4. Mechanisms that Inhibit the Phagocytic Process 
1.4.5. Immune Evasion Mechanisms 

1.5. Microscopy and Staining 

1.5.1. Microscopes and Types of Microscopes 
1.5.2. Compound Stains 
1.5.3. Staining of Acid-Fast Microorganisms 
1.5.4. Stains to Demonstrate Cellular Structures 

1.6. Cultures and Growth of Microorganisms 

1.6.1. General Culture Media 
1.6.2. Specific Culture Media 

1.7. Effect of Chemical and Physical Agents on Microorganisms 

1.7.1. Sterilization and Disinfection 
1.7.2. Disinfectants and Antiseptics Used in Practice 

1.8. Molecular Biology and Its Importance for Infectologists 

1.8.1. Bacterial Genetics 
1.8.2. Polymerase Chain Reaction Tests 

1.9. Indication and Interpretation of Microbiological Studies 

Module 2. Cancer and Immunosuppression 

2.1. The Innate and Adaptive Immune Response 

2.1.1. Cells and Cytokines in Response to Infectious Agents 
2.1.2. Characteristics of the Innate Immune Response 

2.2. Immunosuppression in Different Conditions of Sepsis Patients 

2.2.1. The Role of Cytotoxics in Immunosuppression 
2.2.2. The Role of Cytotoxics in Immunosuppression 
2.2.3. Infection in Transplant Patients 

2.3. The Oncohematological Patient with Sepsis 

2.3.1. Bone Marrow Aplasia 
2.3.2. Neutropenia 
2.3.3. Infections in Patients with Cancer 

2.4. The Diabetic Patient with Sepsis 

2.4.1. The Immune System in Diabetes Mellitus 
2.4.2. Main Infections in the Diabetic Patient 

2.5. Comprehensive Approach to the Immunocompromised Patient with Sepsis 

2.5.1. Diagnostic Considerations 
2.5.2. Therapeutic Measures 

2.6. The Link Between Cancer and Microorganisms 

2.6.1. Oncogenesis and Infection 
2.6.2. Virus and Cancer 

2.6.2.1. Epstein-Barr Virus 
2.6.2.2. Hepatitis B and C Virus 
2.6.2.3. Human Papillomavirus 
2.6.2.4. T-cell Lymphoma/Leukemia Viruses 
2.6.2.5. Herpesvirus Associated with Kaposi’s Sarcoma 

2.7. Bacteria and Cancer 

2.7.1. Helicobacter pylori 

2.8. Parasites and Cancer 

2.8.1. Schistosoma haematobium 
2.8.2. Opisthorchis viverrin 

2.9. Bacteria as Allies Against Cancer 

Module 3. Occupational Accident and Blood-Borne Pathogens 

3.1. Epidemiology of Blood-Borne Pathogen Infections 
3.2. Main Blood-Borne Infections 

3.2.1. Hepatitis B Virus Infection 
3.2.2. Hepatitis C Virus Infection 
3.2.3. HIV/AIDS 

3.3. Diagnostic and Therapeutic Approach to Accidents Involving Blood 

3.3.1. Diagnostic Follow-up of Cases 
3.3.2. Treatment 

3.4. Universal Precautions in Preventing Workplace Accidents 
3.5. Biosafety Measures and the Role of the Epidemiologist in Reducing Biohazards 

3.5.1. Biological Risk 
3.5.2. Biosecurity 
3.5.3. Biosecurity Plans for Biological Protection 

Module 4. Infections in the International Traveller 

4.1. Vaccination for International Travelers 

4.1.1. Main Vaccines for International Travelers 
4.1.2. Vaccination Against Yellow Fever 

4.2. Prophylaxis for Travellers to Tropical Areas 

4.2.1. Pharmacological Treatment Based on the Geographic Area to be Visited 
4.2.2. Glucose-6-Phosphate Dehydrogenase Deficiency and Antimalarial Drugs 
4.2.3. Traveler Prevention Measures in Tropical Areas 

4.3. Traveller’s Diarrhea 

4.3.1. Epidemiology 
4.3.2. Etiology 
4.3.3. Clinical Manifestations 
4.3.4. Diagnosis 
4.3.5. Treatment 

4.4. Health Control for International Travelers 
4.5. Fever After International Travell 

4.5.1. Main Etiologies 
4.5.2. Diagnostic Approach 
4.5.3. Imported Infectious Pathology in the International Traveller 

Module 5. Non-Communicable Chronic Diseases and Infections 

5.1. Infections and the Chronic Inflammatory Response 

5.1.1. Immune System Cells of the Chronic Inflammatory Response to Infections 
5.1.2. The Granulomatous Response and Delayed-type Hypersensitivity 
5.1.3. The Role of Chemical Mediators of the Chronic Inflammatory Response 

5.2. Stress, Immunity and Infectious Agents 

5.2.1. Neurological, Endocrine and Immune Interrelationships 
5.2.2. Stress and the Immune Response 
5.2.3. Chronic Fatigue Syndrome and Infections 

5.3. Atherosclerosis, Cardiovascular Disease and the Role of Infectious Agents 

5.3.1. The Role of Infectious Agents in Atherosclerosis 
5.3.2. Cardiovascular Disease Mortality and its Association with Infectious Agents 
5.3.3. Cardiovascular Mortality in Patients with Pneumonia 

5.4. Digestive Diseases Associated with Infectious Microorganisms 

5.4.1. Gut Flora and its Important Functions 
5.4.2. Peptic Gastroduodenal Disease and Helicobacter pylori 
5.4.3. Inflammatory Bowel Disease and Infections 
5.4.4. Whipple´s Disease 

5.5. Neurological Diseases and Infections 

5.5.1. Dementia and Infections 
5.5.2. Multiple Sclerosis and its Relationship to Certain Infectious Agents 
5.5.3. Guillain-Barré Syndrome, Immunity and Viral Infections 
5.5.4. Parkinson’s Disease and its Association With Infections 

5.6. Endocrinopathies and Infections 

5.6.1. Diabetes Mellitus and Infections 
5.6.2. Chronic Thyroiditis and Infections 

5.7. The Infectious Theory of Rheumatic Diseases 

5.7.1. Rheumatoid Arthritis 
5.7.2. Systemic Lupus Erythematosus 
5.7.3. Seronegative Spondyloarthropathies 
5.7.4. Wegener’s Granulomatosis 
5.7.5. Polymyalgia Rheumatica 

Module 6. The Most Lethal Respiratory Infections 

6.1. Immunology and Defense Mechanisms of the Respiratory System 
6.2. Influenza and Other Lethal Viral Infections 

6.2.1. Influenza Epidemics 
6.2.2. H1N1 Influenza 
6.2.3. Vaccine Against Influenza and the Prevention of Mortality 

6.3. Bacterial Pneumonia: The Captain of the Armies of Death 

6.3.1. Community-Acquired Pneumonia (CAP) 
6.3.2. Intrahospital Pneumonia 
6.3.3. Pneumonia Associated With Healthcare 

6.4. Tuberculosis 

6.4.1. Epidemiology 
6.4.2. Pathobiology 
6.4.3. Classification 
6.4.4. Clinical Presentation 
6.4.5. Diagnosis 
6.4.6. Treatment 

6.5. Loeffler’s Syndrome and Eosinophilic Syndromes 

6.5.1. Pulmonary Phase of Parasites 
6.5.2. Clinical and Radiological Manifestations 
6.5.3. Other Eosinophilic Pneumonias 

6.6. Antimicrobials and the Respiratory System 

6.6.1. Antimicrobials Effective in the Respiratory System 
6.6.2. Immunomodulatory Role of Macrolides in Pneumonias 

Module 7. Urinary Tract and Sexually Transmitted Infections 

7.1. Epidemiology of Urinary Tract Infection 

7.1.1. Factors Explaining the Increased Morbidity of Urinary Tract Infection in Women 

7.2. Immunology of the Urinary System 
7.3. Classification of Urinary Tract Infection 
7.4. Urinary Infection 

7.4.1. Etiology 
7.4.2. Clinical Presentation 
7.4.3. Diagnosis 
7.4.4. Treatment 

7.5. Urinary Tract Infection in the Bladder Catheterised, Prostatic and Elderly Patient 
7.6. Most commonly Used Antimicrobials in Urinary Tract Infections 

7.6.1. Pharmacological Elements 
7.6.2. Antimicrobial Resistance of the Main Bacteria Affecting the Urinary Tract 

7.7. Epidemiological Update on Major STIs 
7.8. Viral STIs 

7.8.1. Perinatal Herpes Simplex 
7.8.2. Viral Hepatitis 
7.8.3. Human Papillomavirus 
7.8.4. HIV 

7.9. Bacterial STIs 

7.9.1. Gonorrhoea 
7.9.2. Syphilis 
7.9.3. Soft Chancre 
7.9.4. Lymphogranuloma Venereum 

7.10. Trichomoniasis and Genital Candidiasis 
7.11. Trichomoniasis: Epidemiology, Aetiology, Clinical Presentation, Diagnosis and Treatment 
7.12. Genital Candidiasis: Epidemiology, Etiology, Clinical Presentation, Diagnosis and Treatment 
7.13. The Syndromic Approach to STIs and Control Measures 

7.13.1. Main Clinical Framework 
7.13.2. STI Control Measures 

7.14. Multidrug-Resistant Gonococcus: Treatment Alternatives 

7.14.1. Global Situation 
7.14.2. Therapeutic Alternatives 

7.15. Current Management of Recurrent Herpes Infection 

7.15.1. Focus Latest Information of Recurrent Herpes Infection 

Module 8. Food-Borne Infections 

8.1. Food-Borne Diseases, a Modern Day Health Problem 

8.1.1. Epidemiology 
8.1.2. Causes of Foodborne Infections 

8.2. Classification of Foodborne Infections 

8.2.1. Intoxications 
8.2.2. Infections 
8.2.3. Toxi-infections 

8.3. Main Aetiological Agents 

8.3.1. Salmonella 
8.3.2. Staphylococci 
8.3.3. Listeria Monocytogenes 
8.3.4. Escherichia coli, 0157;H7 
8.3.5. Clostridium Botulinum 

8.4. Food-Borne Diseases and their Socio-Economic Impact 

8.4.1. Socio-Economic Consequences of the ATS 

8.5. Main Measures for the Control of Food-Borne Infections 

8.5.1. Primary Prevention of ATS 
8.5.2. Health Education 
8.5.3. State Health Control and ATS 

Module 9. Hepatitis, HIV/AIDS Coinfection, and Tuberculosis 

9.1. Viral Hepatitis A 

9.1.1. Virus Characteristics and Replication Cycle 
9.1.2. Clinical Presentation 
9.1.3. Viral Markers 
9.1.4. Evolution and Prognosis 
9.1.5. Treatment 

9.2. Viral Hepatitis B and C 

9.2.1. Virus Characteristics and Replication Cycle 
9.2.2. Clinical Presentation 
9.2.3. Viral Markers 
9.2.4. Evolution and Prognosis 
9.2.5. Treatment 

9.3. Viral Hepatitis D and E 

9.3.1. Virus Characteristics and Replication Cycle 
9.3.2. Clinical Presentation 
9.3.3. Viral Markers 
9.3.4. Evolution and Prognosis 
9.3.5. Treatment 

9.4. Epidemiology of Morbidity and Mortality in Tuberculosis and HIV/AIDS Coinfection 

9.4.1. Incidence 
9.4.2. Prevalence 
9.4.3. Mortality 

9.5. Pathobiology of Tuberculosis and HIV/AIDS Coinfection 

9.5.1. Pathophysiological Alterations in Coinfection 
9.5.2. Pathological Alterations 

9.6. Clinical Manifestations of Coinfection 

9.6.1. Clinical Manifestations of Pulmonary TB 
9.6.2. Clinical Manifestations of Extrapulmonary TB 

9.7. Diagnosis of Tuberculosis in Patients Living with HIV/AIDS 

9.7.1. Diagnostic Studies in Pulmonary TB in HIV/AIDS Patients 

9.8. Integral Care of Patients with Co-infection TB and HIV/AIDS and Therapeutic Considerations 

9.8.1. Comprehensive Care System for TB/HIV/AIDS Patients 
9.8.2. Considerations in Antituberculosis Treatment for Patients with Tuberculosis and HIV/AIDS Coinfection 
9.8.3. Considerations in Antiretroviral Treatment for Patients with Tuberculosis and HIV/AIDS Coinfection 
9.8.4. The Issue of Drug Resistance in Antituberculosis and Antiretroviral in These Patients 

Module 10. Viral Hemorrhagic Diseases and Arboviruses 

10.1. Viral Hemorrhagic Diseases 

10.1.1. Epidemiology 
10.1.2. Classification 
10.1.3. Diagnostic Approach to Viral Hemorrhagic Diseases 
10.1.4. The Development of Vaccines for New Diseases 
10.1.5. Measures for the Control of Viral Hemorrhagic Diseases 

10.2. Ebola Hemorrhagic Fever 

10.2.1. Characteristics and Replicative Cycle of the Virus 
10.2.2. Clinical Presentation 
10.2.3. Diagnosis 
10.2.4. Treatment 

10.3. South American Hemorrhagic Fevers 

10.3.1. Virus Characteristics and Replication Cycle 
10.3.2. Clinical Presentation 
10.3.3. Diagnosis 
10.3.4. Treatment 

10.4. Arbovirus 

10.4.1. Epidemiology 
10.4.2. Vector Control 
10.4.3. Other Arbovirosis 

10.5. Yellow Fever 

10.5.1. Concept 
10.5.2. Replicative Cycle of the Virus 
10.5.3. Clinical Manifestations 
10.5.4. Diagnosis 
10.5.5. Treatment 

10.6. Dengue 

10.6.1. Concept 
10.6.2. Replicative Cycle of the Virus 
10.6.3. Clinical Manifestations 
10.6.4. Diagnosis 
10.6.5. Treatment 

10.7. Chikungunya 

10.7.1. Concept 
10.7.2. Replicative Cycle of the Virus 
10.7.3. Clinical Manifestations 
10.7.4. Diagnosis 
10.7.5. Treatment 

10.8. Zika 

10.8.1. Concept 
10.8.2. Replicative Cycle of the Virus 
10.8.3. Clinical Manifestations 
10.8.4. Diagnosis 
10.8.5. Treatment 

Module 11. Central Nervous System Infections 

11.1. Immune Defense Mechanisms of the CNS 

11.1.1. Defense Mechanisms of the CNS 
11.1.2. Immune Response in the CNS 

11.2. Epidemiology of CNS Infections 

11.2.1. Morbidity 
11.2.2. Mortality 
11.2.3. Risk Factors 

11.3. Microbiological Diagnosis of CNS Infections 

11.3.1. Study of Cerebrospinal Fluid 

11.4. Meningitis 

11.4.1. Etiology 
11.4.2. Clinical Presentation 
11.4.3. Diagnosis 
11.4.4. Treatment 

11.5. Encephalitis 

11.5.1. Etiology 
11.5.2. Clinical Presentation 
11.5.3. Diagnosis 
11.5.4. Treatment 

11.6. Myelitis 

11.6.1. Etiology 
11.6.2. Clinical Presentation 
11.6.3. Diagnosis 
11.6.4. Treatment 

11.7. Antibiotics and the Blood-Brain Barrier 

11.7.1. The Role of the Blood-Brain Barrier 
11.7.2. The Crossing of the Blood-Brain Barrier by Antibiotics 

Module 12. Zoonosis 

12.1. Overview of Zoonosis 

12.1.1. General Concepts and Epidemiology of Zoonosis 
12.1.2. Main Zoonotic Diseases on an International Level 
12.1.3. Prion Zoonosis 
12.1.4. Prions in the Aetiology of Diseases 
12.1.5. Bovine Spongiform Encephalopathy (or Mad Cow Disease) 
12.1.6. Main Zoonosis Control Measures 

12.2. Rabies 

12.2.1. Epidemiology 
12.2.2. Infectious Agents 
12.2.3. Pathobiology 
12.2.4. Clinical Presentation 
12.2.5. Diagnosis 
12.2.6. Treatment 

12.3. Bird Flue 

12.3.1. Epidemiology 
12.3.2. Infectious Agents 
12.3.3. Pathobiology 
12.3.4. Clinical Presentation 
12.3.5. Diagnosis 
12.3.6. Treatment 

12.4. Leptospirosis 

12.4.1. Epidemiology 
12.4.2. Infectious Agents 
12.4.3. Pathobiology 
12.4.4. Clinical Presentation 
12.4.5. Diagnosis 
12.4.6. Treatment 

12.5. Brucellosis 

12.5.1. Epidemiology 
12.5.2. Infectious Agents 
12.5.3. Pathobiology 
12.5.4. Clinical Presentation 
12.5.5. Diagnosis 
12.5.6. Treatment 

12.6. Toxoplasmosis 

12.6.1. Epidemiology 
12.6.2. Infectious Agents 
12.6.3. Pathobiology 
12.6.4. Clinical Presentation 
12.6.5. Diagnosis 
12.6.6. Treatment 

Module 13. Mycobacteriosis and Anaerobic Infections 

13.1. General Overview of Mycobacteriosis 

13.1.1. Microbiological Characteristics of Mycobacteria 
13.1.2. Immune Response to Mycobacterial Infection 
13.1.3. Epidemiology of Major Nontuberculous Mycobacteria Infections 

13.2. Microbiological Methods for the Diagnosis of Mycobacteriosis 

13.2.1. Direct Methods 
13.2.2. Indirect Methods 

13.3. Infection by Mycobacterium avium Intracellulare 

13.3.1. Epidemiology 
13.3.2. Infectious Agents 
13.3.3. Pathobiology 
13.3.4. Clinical Presentation 
13.3.5. Diagnosis 
13.3.6. Treatment 

13.4. Infection by Mycobacterium Kansasii 

13.4.1. Epidemiology 
13.4.2. Infectious Agents 
13.4.3. Pathobiology 
13.4.4. Clinical Presentation 
13.4.5. Diagnosis 
13.4.6. Treatment 

13.5. Leprosy 

13.5.1. Epidemiology 
13.5.2. Infectious Agents 
13.5.3. Pathobiology 
13.5.4. Clinical Presentation 
13.5.5. Diagnosis 
13.5.6. Treatment 

13.6. Other Mycobacteriosis 
13.7. Antimycobacterials 

13.7.1. Pharmacological Characteristics 
13.7.2. Clinical Use 

13.8. Microbiological Characteristics of Anaerobic Germs 

13.8.1. Microbiological Characteristics of Anaerobic Germs 
13.8.2. Microbiological Studies 

13.9. Pulmonary Abscess 

13.9.1. Definition 
13.9.2. Etiology 
13.9.3. Clinical Presentation 
13.9.4. Diagnosis 
13.9.5. Treatment 

13.10. Intraabdominal and Ovarian Tube Abscesses 

13.10.1. Definition 
13.10.2. Etiology 
13.10.3. Clinical Presentation 
13.10.4. Diagnosis 
13.10.5. Treatment 

13.11. Intracerebral Abscess 

13.11.1. Definition 
13.11.2. Etiology 
13.11.3. Clinical Presentation 
13.11.4. Diagnosis 
13.11.5. Treatment 

13.12. Tetanus and Gangrene 

13.12.1. Tetanus: Neonatal and Adult 
13.12.2. Gangrene: Definition, Aetiology, Clinical Presentation, Diagnosis, Treatment 

13.13. Main Antimicrobials against Anaerobic Germs 

13.13.1. Mechanism of Action 
13.13.2. Pharmacogenetics 
13.13.3. Dose 
13.13.4. Introduction 
13.13.5. Adverse Effects 

Module 14. Mycosis and Parasitosis in Infectious Diseases 

14.1. General Aspects on Fungi 

14.1.1. General Features of Fungi 
14.1.2. Immune Response to Fungi 

14.2. Diagnostic Methods for Mycosis 

14.2.1. Direct Methods 
14.2.2. Indirect Methods 

14.3. Superficial Mycosis: Tinea and Epidermatophytosis 

14.3.1. Definition 
14.3.2. Etiology 
14.3.3. Clinical Presentation 
14.3.4. Diagnosis 
14.3.5. Treatment 

14.4. Deep Mycosis 

14.4.1. Cryptococcosis 
14.4.2. Histoplasmosis 
14.4.3. Aspergillosis 
14.4.4. Other Mycosis 

14.5. Update on Antifungals 

14.5.1. Pharmacological Elements 
14.5.2. Clinical Use 

14.6. General Overview of Parasitic Diseases 

14.6.1. General Features of Microbiological Parasites 
14.6.2. Immune Response to Parasites 
14.6.3. Immune Response to Protozoa 
14.6.4. Immune Response to Helminths 

14.7. Diagnostic Methods for Parasites 

14.7.1. Diagnostic Methods for Protozoa 
14.7.2. Diagnostic Methods for Helminths 

14.8. Intestinal Parasites 

14.8.1. Ascariasis 
14.8.2. Enterobiasis 
14.8.3. Hookworm Disease and Necatoriasis 
14.8.4. Trichuriasis 

14.9. Tissue Parasitosis 

14.9.1. Malaria 
14.9.2. Trypanosomiasis 
14.9.3. Schistosomiasis 
14.9.4. Leishmaniasis 
14.9.5. Filariasis 

14.10. Update on Antiparasitics 

14.10.1. Pharmacological Elements 
14.10.2. Clinical Use 

Module 15. Multidrug Resistance and Vaccines 

15.1. The Silent Epidemic of Antibiotic Resistance 

15.1.1. Globalization and Resistance 
15.1.2. Change from Susceptible to Resistant of the Microorganisms 

15.2. The Main Genetic Mechanisms of Antimicrobial Resistance 

15.2.1. Describe the Main Mechanisms of Antimicrobial Resistance 
15.2.2. Selective Antimicrobial Pressure on Antimicrobial Resistance 

15.3. Superbugs 

15.3.1. Pneumococcus Resistant to Penicillin and Macrolides 
15.3.2. Multidrug-Resistant Staphylococci 
15.3.3. Resistant Infections in Intensive Care Units (ICUs) 
15.3.4. Resistant Urinary Tract Infections 
15.3.5. Other Multi-Resistant Microorganisms 

15.4. Resistant Viruses 

15.4.1. HIV 
15.4.2. Influenza 
15.4.3. Hepatitis Viruses 

15.5. Multidrug-resistant Malaria 

15.5.1. Chloroquine Resistance 
15.5.2. Resistance to Other Antimalarials 

15.6. The Main Genetic Studies of Antimicrobial Resistance 

15.6.1. Interpretation of Resistance Studies 

15.7. Global Strategies for Reducing Antimicrobial Resistance 

15.7.1. The Control of Prescribing Antibiotics 
15.7.2. Microbiological Mapping and Clinical Practice Guidelines 

15.8. Overview of Vaccines 

15.8.1. Immunological Basis of Vaccination 
15.8.2. The Process of Vaccination Production 
15.8.3. Quality Control of Vaccines 
15.8.4. Vaccine Safety and Major Adverse Events 
15.8.5. Clinical and Epidemiological Studies for Vaccine Approval 

15.9. The Use of Vaccines 

15.9.1. Vaccine-Preventable Diseases and Vaccination Programs 
15.9.2. Global Experiences of the Effectiveness of Vaccination Programs 
15.9.3. Vaccine Candidates for New Diseases 

Module 16. Rare Infectious Diseases and Other Challenges in Infectiology 

16.1. Overview of Rare Infectious Diseases 

16.1.1. General Concepts 
16.1.2. Epidemiology of Rare or Uncommon Infectious Diseases 

16.2. Bubonic Plague 

16.2.1. Definition 
16.2.2. Etiology 
16.2.3. Clinical Presentation 
16.2.4. Diagnosis 
16.2.5. Treatment 

16.3. Lyme Disease 

16.3.1. Definition 
16.3.2. Etiology 
16.3.3. Clinical Presentation 
16.3.4. Diagnosis 
16.3.5. Treatment 

16.4. Babesiosis 

16.4.1. Definition 
16.4.2. Etiology 
16.4.3. Clinical Presentation 
16.4.4. Diagnosis 
16.4.5. Treatment 

16.5. Rift Valley Fever 

16.5.1. Definition 
16.5.2. Etiology 
16.5.3. Clinical Presentation 
16.5.4. Diagnosis 
16.5.5. Treatment 

16.6. Diphyllobothriasis 

16.6.1. Definition 
16.6.2. Etiology 
16.6.3. Clinical Presentation 
16.6.4. Diagnosis 
16.6.5. Treatment 

16.7. Zygomycosis 

16.7.1. Definition 
16.7.2. Etiology 
16.7.3. Clinical Presentation 
16.7.4. Diagnosis 
16.7.5. Treatment 

16.8. Cysticercosis 

16.8.1. Definition 
16.8.2. Etiology 
16.8.3. Clinical Presentation 
16.8.4. Diagnosis 
16.8.5. Treatment 

16.9. Kuru 

16.9.1. Definition 
16.9.2. Etiology 
16.9.3. Clinical Presentation 
16.9.4. Diagnosis 
16.9.5. Treatment 

16.10. The Re-emergence of Old Diseases: Causes and Effects 

16.10.1. Emerging and New Infectious Diseases that Demand New Approaches for Control 
16.10.2. The Rise of Microbiological Resistance to Antimicrobial Drugs 
16.10.3. Development of New Antibiotics

A unique training experience, key and decisive to boost your professional development"